Vergleich

PCSK9 Recombinant Protein

ArtNr OPCD06025
Hersteller AVIVA Systems Biology
Menge 10 ug
Kategorie
Typ Proteins Recombinant
Applikationen WB, SDS-PAGE
Specific against Human (Homo sapiens)
Host E.coli
Konjugat/Tag Unconjugated; HIS
Purity > 95%
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias convertase subtilisin/kexin type 9 preproprotein;FH3;FHCL3;HCHOLA3;LDLCQ1;NARC1;NARC-1;neural apoptosis regulated convertase 1;Neural apoptosis-regulated convertase 1;PC9;Proprotein convertase 9;proprotein convertase subtilisin/kexin type 9;subtilisin/kexin-like protease PC9.
Lieferbar
Manufacturer - Type
Protein
Manufacturer - Applications
Positive control|Sodium sodecyl sulfate - polyacrylamide gel electrophoresis|Western blot
Manufacturer - Category
Root Catalog/Products/Recombinant Proteins
Manufacturer - Conjugate / Tag
N-terminal His Tag
Molecular Weight
32kDa
Gene symbol
PCSK9
Gene Fullname
proprotein convertase subtilisin/kexin type 9
Protein size
Recombinant
Product format
Freeze-dried Powder. PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
Reconstitution and storage
2°C to 8°C|-80°C
Description of target
Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
Nucleotide accession_num
NM_174936.3
Protein accession_num
NP_777596.2
Protein name
Proprotein convertase subtilisin/kexin type 9
Formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
Concentration
200 ug/mL (prior to lyoph)

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 10 ug
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen